Browse Category

NYSE:GILD News 23 January 2026

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Gilead Sciences shares rose 3.5% to $135.73 Friday, hitting new highs after Phase 3 trial data showed its Trodelvy-Keytruda combo cut the risk of disease progression or death by 35% in metastatic triple-negative breast cancer. Gilead has filed for expanded approval in the U.S. and Europe. Volume reached 8.8 million shares. A Form 144 filing showed executive Deborah Telman plans to sell up to 29,215 shares.

Stock Market Today

Real estate stocks rise as rate-cut bets return; XLRE ends at $41.99 ahead of payrolls and CPI

Real estate stocks rise as rate-cut bets return; XLRE ends at $41.99 ahead of payrolls and CPI

7 February 2026
U.S. real estate stocks rose Friday, with XLRE up 1.8% to $41.99 and VNQ and IYR each gaining 1.6%. The Dow closed above 50,000 for the first time as the 10-year Treasury yield ended at 4.206%. Bank of America downgraded Public Storage and Extra Space Storage, citing weak housing turnover and high borrowing costs. The delayed January jobs report is set for Feb. 11, with CPI due Feb. 13.
Go toTop